THE GIST
Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.
Bayer has been trying to convince investors for years that there is still a good company buried underneath the Monsanto disaster. This quarter helped.
Shares jumped after the company raised its outlook and newer medicines kept growing fast enough to offset some of the decline in older blockbusters. The legal mess is still real, but Bayer is finally starting to look like a company with a future rather than one permanently trapped by its past.
WHAT HAPPENED
Bayer reported a stronger-than-expected third quarter and lifted its full-year profit, cash-flow and debt outlooks, with pharmaceuticals doing most of the heavy lifting. Group sales rose to €10.05 billion (about $11.2 billion) and adjusted EBITDA reached €1.62 billion, both ahead of market expectations.
The star was Nubeqa, Bayer's prostate-cancer drug, whose sales rose 58% and hit roughly €1 billion in the quarter. Kerendia, used to treat chronic kidney disease and heart failure, grew 65% and passed €1 billion of sales over the previous 12 months.
That growth helped pharmaceutical sales rise 6.4% on a currency and portfolio-adjusted basis even as older blockbusters faded. Xarelto sales fell about 31% and Eylea dropped roughly 24% as patent expirations and generic competition continued to bite.
Bayer responded by raising its 2026 adjusted EBITDA forecast to €9.8 billion to €10.3 billion and improving its free-cash-flow outlook by €1 billion. It also expects year-end net debt to come in lower than previously forecast.
The rest of the group looked less exciting. Crop Science earnings fell sharply in what is normally its smallest quarter, while Bayer still posted a €672 million net loss after impairment charges and litigation-related expenses.
WHY IT MATTERS
Bayer's investment story has been warped by Monsanto for so long that almost every good quarter has arrived with an asterisk. The bullish case usually starts with some version of "if the Roundup problem goes away." This time, the operating business is doing more of the work.
Nubeqa and Kerendia are growing quickly enough to provide a credible bridge beyond Xarelto and Eylea, two products that once made Bayer's pharmaceutical division look much safer than it does today. CEO Bill Anderson called the quarter a turning point for pharma, and the numbers support the idea that the division is entering a new growth cycle rather than simply managing decline.
One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.
That matters because Bayer has been fighting two problems at once. Monsanto saddled it with years of litigation, while the pharmaceutical business faced a patent cliff that threatened to weaken the cash-generating engine needed to absorb those legal costs. One of those problems is starting to look more manageable.
The legal picture has also improved. In June, the US Supreme Court sided with Bayer in a key Roundup case, ruling that federal pesticide law blocks certain state failure-to-warn claims. Other types of lawsuits can continue, but the decision narrowed one of the main routes plaintiffs had used against the company.
Bayer is separately seeking approval for a proposed $7.25 billion settlement designed to resolve much of the remaining Roundup litigation. The company still faces tens of thousands of claims and continues to deny that glyphosate causes cancer, so nobody should confuse progress with closure.
But investors can price a known bill far more easily than an endless stream of unpredictable jury verdicts.
The improving drug pipeline gives Bayer another reason to look forward. Asundexian recently became the first approved Factor XIa inhibitor after winning clearance in China for secondary stroke prevention, while newer treatments including Beyonttra are beginning to contribute more meaningfully.
That does not make Bayer suddenly simple. Crop Science remains cyclical and exposed to weak pricing, regulation and weather. Debt is still substantial and litigation will continue consuming cash. What has changed is the balance of the story.
For years, Bayer looked like a decent collection of businesses trapped underneath one of corporate Europe's worst acquisitions. Now the pharmaceutical division is producing enough momentum that investors can start asking what the company might become after the legal mess, rather than only how much the mess will cost.
WHAT'S NEXT
Roundup remains the obvious catalyst. A final decision on Bayer's proposed settlement could remove another large piece of uncertainty, while any setback would remind investors how quickly the old story can return.
Operationally, Nubeqa and Kerendia need to keep delivering as Xarelto and Eylea shrink. Asundexian also has to turn its first approval into a broader global franchise.
Bayer's turnaround is not finished, but the argument around the stock is changing. Investors are finally getting something more interesting to debate than Monsanto.
